ADHD in the News 2015-12-08

Chewable Stimulant OK’d for ADHD

The FDA has approved a chewable tablet form of extended-release methylphenidate, to be sold as QuilliChew ER, for treatment of attention deficit-hyperactivity disorder (ADHD), according to manufacturer Pfizer.

A closer look at study reporting ADHD medications cause sleep problems

Warning: a new study concludes that drugs such as Concerta, Adderall and Vyvanse lead to worse sleep in children. But, parents who are considering whether to treat your child's ADHD with stimulant medication, don't let the results scare your pants off. In fact, put them back on and continue reading.

Using Ritalin to Treat ADHD: Expert Q&A

Methylphenidate (Ritalin, Concerta) is commonly prescribed to treat attention-deficit/hyperactivity disorder (ADHD), but a new analysis finds children taking it are more likely to have sleep problems and decreased appetite, among other issues...We asked a noted expert in ADHD treatment, Andrew Adesman, MD, chief of developmental and behavioral pediatrics at the Steven & Alexandra Cohen Children’s Medical Center of New York, New Hyde Park, to address questions about the new research.

An ADHD Holiday: Managing the symptoms during the season

Many adults have residual symptoms of ADHD, often involving the inattentive form of the disorder, and these symptoms can really interfere with holiday demands. There’s lots of stress around the holiday crunch of course. And with ADHD, there may also be problems with multi-tasking, keeping organized, staying focused on details, and ignoring distractions...Here are a few strategies to use during this time of year.

Bioequivalence for Generic ADHD Medications

Not all medications are alike, particularly when it comes to drugs for the treatment of ADHD. The FDA weighed in on the generic for Concerta back in 2014,1 and now a case series has shown that the generic methylphenidate extended release (ER) formulation that incorporates osmotic controlled-release oral-delivery system (OROS) technology may provide better, longer control of inattention than non-OROS formulations.

Mental health risks highlighted in expectant fathers with epilepsy

Adverse social aspects and life events were more likely to be associated with epilepsy...with self-reported diagnoses of attention deficit hyperactivity disorder (ADHD) and bipolar disorder also more common in epilepsy patients. Additionally, it was shown that a screening tool for ADHD symptoms was a more successful method of diagnosing the condition in these patients than self-reporting.